Crispr Therapeutics AG's market cap is currently $4.48B. The company's EPS TTM is $-4.358; its P/E ratio is ―; Crispr Therapeutics AG is scheduled to report earnings on February 18, 2025, and the estimated EPS forecast is $-1.24. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
Income Statement
Total Revenue	$ 35.00M	$ 371.21M	$ 436.00K	$ 913.08M	$ 543.00K
Gross Profit	$ 37.31M	$ 240.96M	$ -109.81M	$ 895.13M	$ -268.86M
Operating Income	$ -466.57M	$ -222.54M	$ -673.16M	$ 373.53M	$ -354.44M
EBITDA	$ -466.57M	$ -202.70M	$ -648.99M	$ 391.48M	$ -345.25M
Net Income	$ -366.25M	$ -153.61M	$ -650.17M	$ 377.66M	$ -348.87M
Balance Sheet
Cash & Short-Term Investments	$ 1.90B	$ 1.69B	$ 1.82B	$ 2.38B	$ 1.69B
Total Assets	$ 2.24B	$ 2.23B	$ 2.24B	$ 2.75B	$ 1.83B
Total Debt	$ 223.69M	$ 238.63M	$ 244.02M	$ 225.03M	$ 61.43M
Net Debt	$ -74.56M	$ -150.84M	$ 32.14M	$ -698.00M	$ -1.11B
Total Liabilities	$ 309.95M	$ 346.77M	$ 367.58M	$ 352.42M	$ 163.73M
Stockholders' Equity	$ 1.93B	$ 1.88B	$ 1.88B	$ 2.40B	$ 1.66B
Cash Flow
Free Cash Flow	$ -144.68M	$ -272.35M	$ -532.93M	$ 457.27M	$ -256.72M
Operating Cash Flow	$ -142.77M	$ -260.38M	$ -495.74M	$ 538.97M	$ -238.37M
Investing Cash Flow	$ -280.48M	$ 374.65M	$ -258.65M	$ -1.04B	$ -541.17M
Financing Cash Flow	$ 331.98M	$ 62.66M	$ 38.59M	$ 250.94M	$ 1.02B

Currency in USD

Crispr Therapeutics AG Earnings and Revenue History

Income Statement >

Crispr Therapeutics AG Debt to Assets

Balance Sheet >

Crispr Therapeutics AG Cash Flow

Cash Flow >

Crispr Therapeutics AG Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing